Biological Cases associated with biological, n Total of reports of ADR, n ROR 95% CI
Benralizumab 62 4026 0.64 0.50-0.82
Breast Cancer Lung Cancer Malignant Melanoma Pancreatic Carcinoma 4 3 3 3 0.69 0.94 1.92 1.60 0.26-1.84 0.30-2.92 0.62-5.97 0.52-4.96
Mepolizumab 233 9920 0.98 0.86-1.12
Breast Cancer Lung Cancer Prostate Cancer Colon Cancer 19 18 15 7 1.33 2.29 2.26 2.04 0.85-2.09 1.44-3.64 1.36-3.75 0.97-4.28
Reslizumab 8 382 0.87 0.43-1.76
Dupilumab 363 37602 0.40 0.36-0.44
Breast Cancer Cutaneous T-cell lymphoma Lymphoma Lung Cancer 22 16 15 13 0.41 11.11 1.07 0.44 0.27-0.62 6.77-18.23 0.64-1.77 0.25-0.75
Omalizumab1 1380 36164 1.65 1.56-2.74